Research Group
Community Oncology and Prevention Trials
Sponsor
LuZhe Sun
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02642094
To examine whether rapamycin can reduce malignant markers and aberrant mammary
stem/progenitor cells (MaSCs) number in surgical specimens
stem/progenitor cells (MaSCs) number in surgical specimens
Intervention
Rapamycin
Condition
Cancer of Breast
Investigators
LuZhe Sun, PhD, Ismail Jatoi, MD